ARDELYX, INC. (ARDX) Operating Margin
- Operating margin · 12 months: Value -7.86%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -7.86% | Operating income / revenue. Period ending 2026-06-30. $-35.45M ÷ $450.89M × 100 ≈ -7.86% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -35.45M USD | Operating Income (Loss) |
| Revenue | 450.89M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 25.40M USD | Cost of Goods and Services Sold |
| Research and development | 87.21M USD | Research and Development Expense |
| Selling, general and administration | 373.73M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-35.45M | $450.89M | $25.40M | $87.21M | $373.73M | -7.86% |
| 2026-03-31 | $-37.42M | $427.68M | $32.05M | $76.78M | $356.28M | -8.75% |
| 2025-12-31 | $-40.98M | $407.32M | $39.54M | $71.53M | $337.23M | -10.06% |
| 2025-09-30 | $-37.95M | $398.23M | $46.95M | $62.34M | $326.90M | -9.53% |
| 2025-06-30 | $-40.39M | $386.15M | $58.70M | $59.58M | $308.25M | -10.46% |
| 2025-03-31 | $-39.62M | $361.71M | $55.73M | $56.68M | $288.92M | -10.95% |
| 2024-12-31 | $-27.95M | $333.62M | $50.56M | $52.32M | $258.69M | -8.38% |
| 2024-09-30 | $-64.06M | $251.85M | $37.37M | $48.17M | $230.37M | -25.44% |
| 2024-06-30 | $-58.90M | $210.00M | $29.33M | $41.50M | $198.06M | -28.05% |
| 2024-03-31 | $-61.89M | $159.11M | $23.39M | $37.02M | $160.59M | -38.90% |
| 2023-12-31 | $-63.28M | $124.46M | $17.80M | $35.54M | $134.40M | -50.84% |
| 2023-09-30 | $-23.15M | $134.27M | (m) | $35.15M | (m) | -17.24% |
| 2023-06-30 | $-52.42M | $82.87M | (m) | $33.98M | (m) | -63.26% |
| 2023-03-31 | $-62.02M | $63.06M | (m) | $35.44M | (m) | -98.35% |
| 2022-12-31 | $-63.76M | $52.16M | (m) | $35.20M | (m) | -122.24% |
| 2022-09-30 | $-111.17M | $9.01M | (m) | $47.03M | (m) | -1234.04% |
| 2022-06-30 | $-131.53M | $5.20M | (m) | $63.26M | (m) | -2531.39% |
| 2022-03-31 | $-150.15M | $3.98M | (m) | $79.53M | (m) | -3769.72% |
| 2021-12-31 | $-154.35M | $10.10M | (m) | $91.14M | (m) | -1528.63% |
| 2021-09-30 | $-146.72M | $10.88M | (m) | $88.28M | (m) | -1348.86% |
| 2021-06-30 | $-121.64M | $12.42M | (m) | $76.82M | (m) | -979.63% |
| 2021-03-31 | $-101.02M | $12.94M | (m) | $69.67M | (m) | -780.65% |
| 2020-12-31 | $-90.78M | $7.57M | (m) | $65.05M | (m) | -1199.05% |
| 2020-09-30 | $-81.98M | $8.01M | (m) | $61.19M | (m) | -1023.28% |
| 2020-06-30 | $-86.91M | $8.31M | (m) | $66.53M | (m) | -1045.63% |
| 2020-03-31 | $-87.53M | $6.49M | (m) | $67.14M | (m) | -1347.92% |
| 2019-12-31 | $-91.26M | $5.28M | (m) | $71.68M | (m) | -1728.14% |
| 2019-09-30 | $-99.79M | $3.12M | (m) | $79.47M | (m) | -3202.54% |
| 2019-06-30 | $-101.43M | $275.00K | (m) | $79.83M | (m) | -36885.09% |
| 2019-03-31 | $-98.76M | (m) | (m) | $76.40M | (m) | (m) |
| 2018-12-31 | $-90.95M | $2.61M | (m) | $69.37M | (m) | -3488.57% |
| 2018-09-30 | $-52.61M | (m) | (m) | $64.50M | (m) | (m) |
| 2018-06-30 | $-50.10M | (m) | (m) | $61.92M | (m) | (m) |
| 2018-03-31 | $-54.37M | (m) | (m) | $66.45M | (m) | (m) |
| 2017-12-31 | $-65.11M | $42.00M | (m) | $75.48M | (m) | -155.04% |
| 2017-09-30 | $-107.55M | (m) | (m) | $84.53M | (m) | (m) |
| 2017-06-30 | $-115.53M | (m) | (m) | $94.03M | (m) | (m) |
| 2017-03-31 | $-117.80M | (m) | (m) | $97.30M | (m) | (m) |
| 2016-12-31 | $-112.89M | (m) | (m) | $94.16M | (m) | (m) |
| 2016-09-30 | $-98.30M | (m) | (m) | $80.73M | (m) | (m) |
| 2016-06-30 | $-87.18M | (m) | (m) | $70.58M | (m) | (m) |
| 2016-03-31 | $-49.43M | (m) | (m) | $52.94M | (m) | (m) |
| 2015-12-31 | $-29.39M | $24.03M | (m) | $39.88M | (m) | -122.32% |
| 2015-09-30 | $-16.45M | $30.36M | (m) | $34.49M | (m) | -54.16% |
| 2015-06-30 | $1.72M | $37.96M | (m) | $25.48M | (m) | 4.52% |
| 2015-03-31 | $-4.59M | $28.96M | (m) | $24.46M | (m) | -15.85% |
| 2014-12-31 | $-1.56M | $31.62M | (m) | $25.90M | (m) | -4.95% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $30.92M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-2.87M | $28.93M | (m) | $28.09M | (m) | -9.90% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-8.80M | $5.41M | (m) | $10.18M | (m) | -162.75% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |